TheraRadar

Pharma Intelligence, Simplified

Landscape → Oncology

Prostate Cancer

1,607 clinical trials

857 active
/
1607 total (since 2015)
306
Phase 1 Active
624 total
534
Phase 2 Active
958 total
153
Phase 3 Active
249 total
25
Phase 4 Active
55 total

Top Sponsors (Industry)

Sorted by active Active Done Failed
Novartis 24 3 3
Johnson & Johnson 17 6 2
AstraZeneca 15 7 1
Jiangsu HengRui Medicine Co., Ltd. 12 6 2
Merck 9 7 2
Pfizer 8 4 2
Bayer 7 8 0
Amgen 6 1 3
Eli Lilly 6 2 0
Astellas Pharma Global Development, Inc. 4 3 1
Exelixis 4 1 1
Clarity Pharmaceuticals Ltd 3 1 1
Telix Pharmaceuticals (Innovations) Pty Limited 3 2 0
Aragon Pharmaceuticals, Inc. 3 1 0
Daiichi Sankyo 3 0 0
NCT06931340 RECRUITING
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology n=1,260
NCT06629779 RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer n=900
NCT06551324 RECRUITING
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer n=600
NCT07028853 RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer n=1,000
NCT05154162 ACTIVE NOT RECRUITING
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI
Peter MacCallum Cancer Centre, Australia n=660
NCT03495427 RECRUITING
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
H. Lee Moffitt Cancer Center and Research Institute n=60
NCT06136650 RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Merck Sharp & Dohme LLC n=1,314
NCT04423211 RECRUITING
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ECOG-ACRIN Cancer Research Group n=804
NCT03274687 ACTIVE NOT RECRUITING
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology n=296
NCT06925737 RECRUITING
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Merck Sharp & Dohme LLC n=1,440
NCT06136624 RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Merck Sharp & Dohme LLC n=1,310
NCT03574571 ACTIVE NOT RECRUITING
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center n=732
NCT07213674 RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen n=750
NCT06650579 RECRUITING
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University n=72
NCT05939414 RECRUITING
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Novartis Pharmaceuticals n=450
NCT06780670 RECRUITING
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Novartis Pharmaceuticals n=443
NCT06855277 RECRUITING
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Novartis Pharmaceuticals n=940
NCT07427043 RECRUITING
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
Brigham and Women's Hospital n=300
NCT07426094 NOT YET RECRUITING
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,600
NCT07426055 NOT YET RECRUITING
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Affidea Nu-med Center of Oncological DIagnostics and Therapy n=1,200
NCT04689828 ACTIVE NOT RECRUITING
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals n=469
NCT05794906 ACTIVE NOT RECRUITING
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Bayer n=985
NCT06235151 RECRUITING
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Curium US LLC n=439
NCT03395197 ACTIVE NOT RECRUITING
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
Pfizer n=1,054
NCT04497844 ACTIVE NOT RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Janssen Research & Development, LLC n=696
NCT07225946 RECRUITING
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC n=800
NCT02531516 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc. n=1,503
NCT04557059 ACTIVE NOT RECRUITING
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Janssen Pharmaceutica N.V., Belgium n=694
NCT05884398 ACTIVE NOT RECRUITING
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Janssen Research & Development, LLC n=420
NCT06952803 RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
AstraZeneca n=700
NCT06439225 RECRUITING
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Canadian Cancer Trials Group n=236
NCT04720157 ACTIVE NOT RECRUITING
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals n=1,145
NCT04076059 ACTIVE NOT RECRUITING
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Astellas Pharma China, Inc. n=180
NCT04455750 ACTIVE NOT RECRUITING
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology n=61
NCT06691984 RECRUITING
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen n=675
NCT06563388 RECRUITING
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Roswell Park Cancer Institute n=800
NCT07311694 RECRUITING
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=370
NCT02489318 ACTIVE NOT RECRUITING
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Aragon Pharmaceuticals, Inc. n=1,052
NCT05946213 RECRUITING
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology n=1,209
NCT07241416 RECRUITING
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=156
NCT03732820 ACTIVE NOT RECRUITING
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
AstraZeneca n=895
NCT06825091 RECRUITING
Is Adaptive SBRT for Prostate vs Image-guided Radiotherapy a True Evolution (ASPIRE)
University Health Network, Toronto n=320
NCT06764485 RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Celgene n=960
NCT07365995 NOT YET RECRUITING
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE n=736
NCT06470243 RECRUITING
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
SWOG Cancer Research Network n=528
NCT06120491 RECRUITING
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
AstraZeneca n=1,800
NCT06205316 RECRUITING
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic n=118
NCT04493853 ACTIVE NOT RECRUITING
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
AstraZeneca n=1,012
NCT03767244 ACTIVE NOT RECRUITING
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Janssen Research & Development, LLC n=2,517
NCT05838716 RECRUITING
Vitamin D for Prostate Endocrine Therapy
University of Rochester n=240
NCT03367702 ACTIVE NOT RECRUITING
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NRG Oncology n=692
NCT05050084 RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology n=2,050
NCT04134260 RECRUITING
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology n=586
NCT06592924 RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Canadian Cancer Trials Group n=830
NCT04513717 ACTIVE NOT RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology n=2,753
NCT04647526 ACTIVE NOT RECRUITING
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company n=455
NCT06122584 RECRUITING
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
ABX advanced biochemical compounds GmbH n=380
NCT06235697 RECRUITING
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
Canadian Cancer Trials Group n=710
NCT07333066 NOT YET RECRUITING
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD n=320
NCT03258320 RECRUITING
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
Shanghai Jiao Tong University School of Medicine n=300
NCT07293585 RECRUITING
Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment
Jonsson Comprehensive Cancer Center n=200
NCT04446117 ACTIVE NOT RECRUITING
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
Exelixis n=575
NCT03701581 RECRUITING
4-aminopyridine Treatment for Nerve Injury
John Elfar n=70
NCT06056830 RECRUITING
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Clarity Pharmaceuticals Ltd n=383
NCT06970847 RECRUITING
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Clarity Pharmaceuticals Ltd n=220
NCT04821622 ACTIVE NOT RECRUITING
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Pfizer n=599
NCT05597878 RECRUITING
Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy
Wake Forest University Health Sciences n=100
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT07260435 RECRUITING
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
Nick Beije n=400
NCT05786716 RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Cancer Research UK n=30
NCT05171816 ACTIVE NOT RECRUITING
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
AstraZeneca n=110
NCT03987386 ACTIVE NOT RECRUITING
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center n=186
NCT06274047 RECRUITING
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center n=120
NCT04263025 RECRUITING
AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
Hackensack Meridian Health n=100
NCT04787744 RECRUITING
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
VA Office of Research and Development n=464
NCT07209878 RECRUITING
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University n=100
NCT07200830 NOT YET RECRUITING
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Alliance for Clinical Trials in Oncology n=1,524
NCT06320067 RECRUITING
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
University College, London n=3,360
NCT05520255 RECRUITING
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
University of Alberta n=2,800
NCT05974774 RECRUITING
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
European Organisation for Research and Treatment of Cancer - EORTC n=1,600
NCT02194842 ACTIVE NOT RECRUITING
Phase III Radium 223 mCRPC-PEACE III
European Organisation for Research and Treatment of Cancer - EORTC n=446
NCT03678025 RECRUITING
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network n=1,273
NCT07052214 RECRUITING
PSMA PET Combined With MRI for the Detection of PCa
Telix Pharmaceuticals (Innovations) Pty Limited n=204
NCT04191096 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Merck Sharp & Dohme LLC n=1,251
NCT03348670 ACTIVE NOT RECRUITING
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair n=600
NCT06986083 RECRUITING
A Study of Changes to Prostate Procedures
Memorial Sloan Kettering Cancer Center n=800
NCT04181203 ACTIVE NOT RECRUITING
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
UNICANCER n=490
NCT03834493 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
Merck Sharp & Dohme LLC n=1,244
NCT06520345 RECRUITING
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited n=430
NCT05448547 RECRUITING
Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer
Sven Löffeler n=980
NCT05796973 RECRUITING
Measuring Oncological Value of Exercise and Statin
Tampere University Hospital n=240
NCT05288166 ACTIVE NOT RECRUITING
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company n=925
NCT03819101 RECRUITING
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris n=1,210
NCT04115007 ACTIVE NOT RECRUITING
Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
UNICANCER n=550
NCT06625970 RECRUITING
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
UNICANCER n=700
NCT03531099 ACTIVE NOT RECRUITING
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
Hospices Civils de Lyon n=108
NCT03769766 RECRUITING
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
University of Texas Southwestern Medical Center n=291
NCT02804815 ACTIVE NOT RECRUITING
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London n=11,000
NCT06626022 RECRUITING
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
University of Alberta n=1,284
NCT06972511 RECRUITING
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
RenJi Hospital n=120
NCT04833426 RECRUITING
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Canisius-Wilhelmina Hospital n=140
NCT06945315 RECRUITING
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
Icahn School of Medicine at Mount Sinai n=196
NCT05678322 ACTIVE NOT RECRUITING
Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NYU Langone Health n=26
NCT03706365 ACTIVE NOT RECRUITING
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Eli Lilly and Company n=393
NCT06112990 RECRUITING
Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression
University of Utah n=200
NCT06922903 NOT YET RECRUITING
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
Yunhe Pharmaceutical (Tianjin) Co., Ltd n=240
NCT06922929 NOT YET RECRUITING
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
Yunhe Pharmaceutical (Tianjin) Co., Ltd n=110
NCT03903835 RECRUITING
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Karolinska Institutet n=750
NCT04302454 ACTIVE NOT RECRUITING
Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy
University Medical Center Groningen n=280
NCT05169112 RECRUITING
Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
Ottawa Hospital Research Institute n=72
NCT04794777 RECRUITING
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
Stefan Carlsson n=450
NCT04557501 ACTIVE NOT RECRUITING
PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=800
NCT02692105 ACTIVE NOT RECRUITING
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
British Columbia Cancer Agency n=60
NCT03525288 ACTIVE NOT RECRUITING
PSMA-PET Guided Radiotherapy
Centre hospitalier de l'Université de Montréal (CHUM) n=130
NCT03851640 RECRUITING
A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hinova Pharmaceuticals Inc. n=417
NCT06565247 RECRUITING
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
Region Västerbotten n=60
NCT06855589 NOT YET RECRUITING
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
Charles LeMoyne Hospital n=400
NCT06837896 NOT YET RECRUITING
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd. n=110
NCT05676203 ACTIVE NOT RECRUITING
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients
Jena University Hospital n=250
NCT05381103 RECRUITING
PSMA-PET to Guide Prostatectomy
Five Eleven Pharma, Inc. n=288
NCT05348577 ACTIVE NOT RECRUITING
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
AstraZeneca n=1,035
NCT06768255 NOT YET RECRUITING
Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC
Ding-Wei Ye n=400
NCT06754085 RECRUITING
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
HTA Co., Ltd. n=131
NCT04691804 ACTIVE NOT RECRUITING
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. n=496
NCT06496581 RECRUITING
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER n=500
NCT02303327 ACTIVE NOT RECRUITING
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Sir Mortimer B. Davis - Jewish General Hospital n=307
NCT02685397 ACTIVE NOT RECRUITING
Management of Castration-Resistant Prostate Cancer with Oligometastases
Sir Mortimer B. Davis - Jewish General Hospital n=102
NCT02799706 ACTIVE NOT RECRUITING
Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC n=885
NCT04916613 RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER n=300
NCT05613023 RECRUITING
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
Institute of Cancer Research, United Kingdom n=1,128
NCT06585007 RECRUITING
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Universitaire Ziekenhuizen KU Leuven n=246
NCT06490328 RECRUITING
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Dongkook Pharmaceutical Co., Ltd. n=154
NCT05847348 RECRUITING
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
Telix Pharmaceuticals (Innovations) Pty Limited n=110
NCT05352178 RECRUITING
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Universitaire Ziekenhuizen KU Leuven n=873
NCT03594760 RECRUITING
PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Centre hospitalier de l'Université de Montréal (CHUM) n=1,000
NCT05799248 RECRUITING
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
MidLantic Urology n=113
NCT05622162 ACTIVE NOT RECRUITING
Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7
ITEL Telecomunicazioni Srl n=106
NCT06350825 RECRUITING
Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
The First Affiliated Hospital with Nanjing Medical University n=200
NCT05116475 RECRUITING
Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie n=152
NCT06282588 RECRUITING
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
Cancer Research Antwerp n=493
NCT04642027 RECRUITING
PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy
University Medical Center Groningen n=538
NCT06177015 RECRUITING
Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
The First Affiliated Hospital with Nanjing Medical University n=200
NCT04242017 RECRUITING
Long-term Better Than Short-term ADT With Salvage RT
Universitaire Ziekenhuizen KU Leuven n=394
NCT03459820 ENROLLING BY INVITATION
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
Sir Mortimer B. Davis - Jewish General Hospital n=1,500
NCT05781217 RECRUITING
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic n=534
NCT05983783 RECRUITING
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
The First Affiliated Hospital with Nanjing Medical University n=200
NCT04136353 ACTIVE NOT RECRUITING
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
University of Sydney n=1,100
NCT05956639 RECRUITING
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
The First Affiliated Hospital with Nanjing Medical University n=100
NCT04654338 RECRUITING
2 Ablative RadioTherapy Treatments for Prostate Cancer
Sunnybrook Health Sciences Centre n=30
NCT05019846 RECRUITING
SRT Versus SRT+ADT in Prostate Cancer
Marco Lorenzo Bonu n=310
NCT05232578 NOT YET RECRUITING
Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
General University Hospital, Prague n=380
NCT03824275 ACTIVE NOT RECRUITING
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Columbia University n=129
NCT05009290 RECRUITING
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Jiangsu HengRui Medicine Co., Ltd. n=1,256
NCT04736199 COMPLETED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Bayer n=669
NCT04876651 TERMINATED
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Ltd n=16
NCT06235099 COMPLETED
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
Curium US LLC n=235
NCT07413120 COMPLETED
Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery
Incheon St.Mary's Hospital n=40
NCT03070886 COMPLETED
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology n=612
NCT03009981 COMPLETED
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC. n=504
NCT02799602 COMPLETED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
Bayer n=1,306
NCT02677896 COMPLETED
A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Astellas Pharma Global Development, Inc. n=1,150
NCT04838613 COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 in BCR
Novartis Pharmaceuticals n=190
NCT04838626 COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
Novartis Pharmaceuticals n=195
NCT04934722 COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
Merck Sharp & Dohme LLC n=186
NCT04186845 COMPLETED
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics n=391
NCT05590793 COMPLETED
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
Ipsen n=195
NCT05605964 COMPLETED
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc. n=387
NCT05137561 COMPLETED
Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed Cognitive Fusion TRUS Guided Prostate Biopsy (PROBIOP)
Post Graduate Institute of Medical Education and Research, Chandigarh n=217
NCT02975934 COMPLETED
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
pharmaand GmbH n=405
NCT05458856 COMPLETED
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
Ipsen n=147
NCT05547386 COMPLETED
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Mayo Clinic n=163
NCT03834506 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
Merck Sharp & Dohme LLC n=1,030
NCT04742361 COMPLETED
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
ABX advanced biochemical compounds GmbH n=136
NCT04100018 COMPLETED
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Bristol-Myers Squibb n=1,030
NCT03072238 COMPLETED
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
Hoffmann-La Roche n=1,101
NCT04261777 TERMINATED
Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients
Saving Patients' Lives Medical B.V. n=172
NCT06984159 COMPLETED
The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart.
Changchun GeneScience Pharmaceutical Co., Ltd. n=137
NCT03834519 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Merck Sharp & Dohme LLC n=793
NCT06795191 WITHDRAWN
Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer
Foresee Pharmaceuticals Co., Ltd.
NCT06795178 WITHDRAWN
Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer
Foresee Pharmaceuticals Co., Ltd.
NCT03936218 COMPLETED
Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer
Eurofarma Laboratorios S.A. n=94
NCT03822845 COMPLETED
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
Michael Graham PhD, MD n=6
NCT04186819 COMPLETED
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics n=356
NCT03862170 TERMINATED
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
CR-CSSS Champlain-Charles-Le Moyne n=158
NCT03103321 COMPLETED
Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer
Alliance for Clinical Trials in Oncology n=158
NCT03511664 COMPLETED
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Endocyte n=861
NCT02220829 COMPLETED
Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy
Sir Mortimer B. Davis - Jewish General Hospital n=148
NCT03031821 TERMINATED
Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Canadian Urologic Oncology Group n=168
NCT03777982 TERMINATED
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute n=12
NCT03056638 TERMINATED
Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer
Memorial Sloan Kettering Cancer Center n=56
NCT03850795 TERMINATED
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Hinova Pharmaceuticals USA, Inc. n=104
NCT03016312 COMPLETED
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Hoffmann-La Roche n=759
NCT04907227 TERMINATED
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
Merck Sharp & Dohme LLC n=81
NCT03389451 COMPLETED
68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
Michael Graham PhD, MD n=30
NCT04676334 COMPLETED
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
pharmaand GmbH n=34
NCT04684628 SUSPENDED
68Ga-PSMA PET/CT in Prostate Cancer
University of Saskatchewan n=500
NCT03388346 COMPLETED
68Ga PSMA in Preprostatectomy Patients
Michael Graham PhD, MD n=22
NCT04644822 COMPLETED
Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.
Centre for Probe Development and Commercialization n=100
NCT04844749 TERMINATED
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
Veru Inc. n=105
NCT04887506 COMPLETED
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics n=107
NCT04409288 TERMINATED
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Chinese University of Hong Kong n=74
NCT03001869 COMPLETED
68Ga-PSMA PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital n=540
NCT05197257 COMPLETED
68Ga-PSMA-11 PET in Patients With Prostate Cancer
University of Colorado, Denver n=39
NCT02987543 COMPLETED
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
AstraZeneca n=387
NCT05771896 WITHDRAWN
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
GenesisCare USA
NCT05098327 WITHDRAWN
Pioglitazone and Insulin Resistance in ADT
State University of New York at Buffalo
NCT04914195 COMPLETED
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
Bharat Serums and Vaccines Limited n=155
NCT05363644 WITHDRAWN
BioDFence® G3 For Full Nerve-Sparing Robotic-Assisted Radical Prostatectomy
AdventHealth
NCT02659527 COMPLETED
PET/MRI in Patients With Suspected Prostate Cancer
Medical University of Vienna n=220
NCT02624518 COMPLETED
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Andrei Iagaru n=122
NCT03103152 COMPLETED
A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression
Queen Mary University of London n=104
NCT02438007 TERMINATED
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
LTN PHARMACEUTICALS, INC. n=953
NCT03921996 TERMINATED
Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer
Swiss Cancer Institute n=57
NCT05744115 TERMINATED
Ga-68-PSMA-11 in Men With Prostate Cancer
Timothy Hoffman n=38
NCT04627896 COMPLETED
Targeted Microwave Focal Therapy
A.O.U. Città della Salute e della Scienza n=11
NCT04854993 COMPLETED
Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=34
NCT04457245 TERMINATED
Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
Jonsson Comprehensive Cancer Center n=54
NCT02745587 TERMINATED
Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.
University Hospital, Ghent n=69
NCT04237584 TERMINATED
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
MANA RBM n=23
NCT02663908 TERMINATED
A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
Ferring Pharmaceuticals n=545
NCT02961257 COMPLETED
Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie n=196
NCT03295565 COMPLETED
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
The Netherlands Cancer Institute n=100
NCT02678351 COMPLETED
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Andrei Iagaru n=74
NCT03085095 COMPLETED
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Myovant Sciences GmbH n=1,134
NCT02673151 COMPLETED
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Andrei Iagaru n=61
NCT03800784 WITHDRAWN
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03353740 COMPLETED
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Thomas Hope n=346
NCT04563936 COMPLETED
Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®
Luye Pharma Group Ltd. n=290
NCT03803475 COMPLETED
Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients
Thomas Hope n=485
NCT02981368 COMPLETED
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Progenics Pharmaceuticals, Inc. n=385
NCT02940262 COMPLETED
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy
Jonsson Comprehensive Cancer Center n=1,138
NCT04102553 COMPLETED
F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
ABX advanced biochemical compounds GmbH n=200
NCT03739684 COMPLETED
Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Progenics Pharmaceuticals, Inc. n=208
NCT03532308 TERMINATED
Nutrition and Prostate Cancer
Yale University n=19
NCT02834416 COMPLETED
ADT Exercise Trial and Economic Analysis
University Health Network, Toronto n=38
NCT03404648 COMPLETED
Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI
Mayo Clinic n=19
NCT03911310 COMPLETED
[18F]PSMA-11 PET/CT Phase 3 Clinical Study
University Hospital, Ghent n=96
NCT02919111 COMPLETED
Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients
University of California, San Francisco n=299
NCT04225299 WITHDRAWN
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
NCT03488810 WITHDRAWN
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
NCT02887976 COMPLETED
Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201
GU Research Network, LLC n=2
NCT03261999 COMPLETED
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Foresee Pharmaceuticals Co., Ltd. n=144
NCT02918357 COMPLETED
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
University of California, San Francisco n=385
NCT02615067 COMPLETED
Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer
Molecular Insight Pharmaceuticals, Inc. n=531
NCT02712320 COMPLETED
Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg
Foresee Pharmaceuticals Co., Ltd. n=30
NCT02680041 COMPLETED
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
Blue Earth Diagnostics n=221
NCT02551341 COMPLETED
Lung Protective Ventilation During Robotic Assisted Prostatectomy
Jørgen Bjerggaard Jensen n=24
NCT02840552 COMPLETED
The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer
Sir Mortimer B. Davis - Jewish General Hospital n=60
NCT02526784 COMPLETED
A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer
Ferring Pharmaceuticals n=120

Data: ClinicalTrials.gov